Navigation Links
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Date:4/17/2009

Fort Collins, CO, April 17, 2009 / b3c newswire / - Addressing significant product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products. InVitria’s Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA). 
  • The advantages of Recombinant Albumin-DX include:
  • Reduce non-specific binding and improve specificity;
  • Improved consistency due to recombinant manufacturing;
  • Improved stabilization of sensitive proteins and biomarkers; and
  • Reduce occupational safety risk and regulatory burden of handling human or animal blood products.
Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative. In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).  
 
“InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise,” said the company’s President and CEO Scott Deeter. “Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek.”
 
To receive a Recombinant Albumin-DX or DX Lipid-Free product materials packet, please contact InVitria’s customer service specialists at 1-800-916-8311 or by e-mail at info@InVitria.com.
ws" timex="4/17/2009 5:26:57 AM" dirsub="(bsp; About InVitria InVitria develops ...)" id="8019" index="biology" dir="InVitria Announces Launch of Recombinant Albumin for Diagnostics" dir2="InVitria Announces Launch of Recombinant Albumin for D..." keywords1=",biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters" keywords="InVitria,Announces,Launch,of,Recombinant,Albumin,for,Diagnostics" description="bsp; About InVitria InVitria develops manufactures and markets a portfolio of cell culture and diagnostic reagents. These products are used in cell culture biopharmaceutical formulation stem cell & regenerative medicine medical devices and diagnostics.   Learn more about InVitria’s products at a target _blank href http://www.in" url=u&"/biology-news-1/InVitria-Announces-Launch-of-Recombinant-Albumin-for-Diagnostics-8019-2/" title="InVitria%20Announces%20Launch%20of%20Recombinant%20Albumin%20for%20Diagnostics" %> InVitria Announces Launch of Recombinant Albumin for D... (Fort Collins CO April 17 2009 / b3c news...)
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Date:4/17/2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology: